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To assess the time trends and survivals after operations for primary lung 
cancer, the cases of 845 consecutive patients who underwent horacotomy 
between 1976 and 1990 were retrospectively reviewed by groups correspond- 
ing to year of the operation (the early period was 1976 to 1980, n = 208; the 
middle period was 1981 to 1985, n = 291, and the late period was 1986 to 
1990, n = 346). The 5-year survivals at the early, the middle, and the late 
periods were 31.5%, 39.0%, and 54.0%, respectively, with significant im- 
provement particularly at the late period (p < 0.05 for the early period vs 
the middle period, p < 0.01 for the early or middle period vs the late 
period); the improvement was caused by increase in the ratio of patients 
with stage I disease (20.7% at the early period, 32.0% at the middle period, 
44.2% at the late period), increase in the rates of complete tumor resection 
with lymph node dissection (57.2%, 68.0%, 74.3%, respectively), and de- 
crease in the rates of operation-related eath (3.8%, 3.4%, 0.9%, respec- 
tively). The postoperative prognosis of patients with stage II disease at the 
late period (5-year survival 74.8%) showed significant improvement com- 
pared with the other periods. Moreover, the prognosis of patients with stage 
IIIa, pN2 disease (5-year survival 41.5%) showed significant improvement, 
which was caused by the significant decrease in patients with pT3 N2 M0 
disease and poor prognosis. (J Thorac Cardiovasc Surg 1996;112:349-55) 
T he prognosis after operation for primary lung cancer (PLC) remains poor despite recent ad- 
vances both in diagnostic imaging, such as computed 
tomography (CT) and magnetic resonance imaging, 
and in adjuvant therapy. Five-year survivals have 
been reported to range between approximately 20% 
to 30%. 1 Only a few reports, 2 however, have been 
published with respect o the time trends of survival 
after operation for PLC. Moreover, because the 
present international staging system for PLC 3 was 
revised in 1986, it is difficult to compare prognoses 
based on the old staging system with those based on 
the current staging system. 4 To determine whether 
the survival of patients who underwent operations 
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for PLC did improve, we examined the time trends 
for survival after operation for PLC during the past 
15 years at a single institution. 
Patients and methods 
A total of 845 patients who underwent thoracotomy for 
PLC at the Department of Thoracic Surgery, Chest Dis- 
ease Research Institute, Kyoto University, during the past 
15 years (from January 1, 1976, to December 31, 1990) 
were retrospectively reviewed and studied. Patients were 
grouped according to the year when thoracotomy was 
performed: the early period (from 1976 to 1980), the 
middle period (from 1981 to 1985), and the late period 
(from 1986 to 1990). There were 629 male and 216 female 
patients. Mean age at thoracotomy was 61.5 -+ 9.8 years 
(mean _+ standard eviation, range 17 to 83 years). 
Investigation was performed with all inpatient medical 
records, chest radiographs, whole-body CT films, bone 
and gallium scanning data, operative records, and patho- 
logic specimens. For patients who underwent operation in 
1981 and later, whole-body (ST and bone and gallium scan 
were routinely taken. Mediastinoscopy was not routinely 
employed. Histologic typing was conducted according to 
the classification of the World Health Organization. 5 
Tumor extent was evaluated according to the current 
TNM classification, revised in 1986; 3 reevaluation accord- 
ing to the present TNM classification was performed for 
patients who underwent operation before 1986. Complete 
tumor resection was defined as no microscopic ancers 
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Table I. Characteristics of patients 
Year of operation 
1976 to 1980 1981 to 1985 1986 to 1990 
(n = 208) (n = 291) (n = 346) Time trend P 
Sex (male:female) 














213:78 256:90 0.50 
61.2 -+ 10.0 63.0 -+ 9.1"I" 
113 (38.8%):~ 108 (31.1%)*§ <0.01 
129 (44.3%):) 175 (50.4%)* <0.01 
18 (6.2%) 22 (6.2%) 0.11 
20 (6.9%) 22 (6.2%) 0.08 
11 22 
Time trend analysis by X a test. 6
*p < 0.01, 1976 to 1980 vs 1986 to 1990. 
?p < 0.05, 1981 to 1985 vs 1986 to 1990. 
~p < 0.05, 1976 to 1980 vs 1981 to i985. 
§p < 0.01, 1981 to 1985 vs 1986 to 1990. 
identified, neither in the resection margins of the tumor 
nor in the highest mediastinal lymph nodes. In patients 
who did not undergo lymph node dissection, routine 
sampling of various lymph node stations was performed 
intraoperatively to determine the pathologic staging. Fol- 
low-up of the postoperative clinical course was conducted 
through out-patient medical records and inquiries by 
telephone or letter. For patients referred to other hospi- 
tals for postoperative follow-up, medical information con- 
cerning the cause and date of death was obtained from 
those hospitals. Follow-up was complete and survival 
could be determined accurately and reliably across the 
three periods of the study. The day of the thoracotomy for 
the primary pulmonary lesion was regarded as the starting 
day for measuring postoperative survival. 
Statistical methods. Counts were compared with the 
use of )(2 analysis; X 2 test for trend 6was employed for 
analysis of time trends. Continuous data with normal 
distribution were compared with the Student's t test; those 
without normal distribution were compared with the 
Mann-Whitney U test. Survival was analyzed by the 
Kaplan-Meier method, 7 and evaluation of the difference 
was conducted by log-rank test. 8 Multivariance analysis 
of the prognostic factors was conducted by Cox's re- 
gression model. 9Differences with p values not greater 
than 0.05 were regarded as statistically significant. All 
the above-mentioned statistical analysis was performed 
with SPSS for Windows software system (SPSS Inc., 
Chicago, Ill.). 
Results 
Distribution of patients. There were no signifi- 
cant sex differences among the three groups. The 
mean ages at the early, middle, and late periods 
were 59.7, 61.2, and 63.0 years, respectively, with 
significant increases at the later periods. With re- 
spect o the histologic type, the ratio of patients with 
adenocarcinoma showed significant increase at the 
middle and late periods (Table I). 
With regard to staging (Table II), the ratio of 
stage I disease increased significantly at the middle 
and the late periods, mainly as a result of an 
increase in the ratio of pT1 NO M0 disease at the 
late period (8.7% at the early period, 17.9% at the 
middle period, 25.4% at the late period). The ratio 
of patients with p-stage II disease in all the study 
periods was about 10%. The ratio of patients with 
p-stage IIIa disease showed significant decrease in 
the late period, mainly as a result of decrease in the 
ratio of patients with pT3 N2 M0 disease (13.0% at 
the early period, 6.1% at the middle period, 2.6% at 
the late period). There were no significant changes 
in the ratio of patients with p-stage IIIb or p-stage 
IV disease. 
Exploratory thoraeotomy, complete resection, 
and operation-related eath. The rate of explor- 
atory thoracotomy significantly decreased at the late 
period (9.1% at the early period, 4.8% at the middle 
period, 2.9% at the late period; Table III). Com- 
plete tumor resection with lymph node dissection 
was performed in 120, 198, and 258 patients at the 
early, middle, and late periods, respectively, com- 
plete tumor resection without lymph node dissection 
was performed in six, three, and 13 patients, respec- 
tively. The rate of complete tumor resection with 
lymph node dissection showed significant increase at 
the later periods. The rates of operation-related 
death at the early, middle, and late periods were 
3.8%, 3.4%, and 0.9%, respectively, showing signif- 
icant decrease at the later period. 
Survival after operation. The 5-year survival in- 
creased significantly, from 31.5% at the early period 
to 39.0% at the middle period and 54.0% at the late 
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Table II. Pathologic staging of disease 
Year of operation 
1976 to 1980 1981 to 1985 1986 to 1990 
(n = 208) (n = 291) (n = 346) 
No. % No. % No. % Time trend P 
Stage I (n = 289) 
T1 NO M0 (n = 158) 
T2 NO M0 (n = 131) 
Stage II (n = 72) 
T1 N1 M0 (n = 25) 
T2 N1 M0 (n = 47) 
Stage I I Ia (n = 287) 
T3 N0-1 )dO (n = 116) 
T1-2 N2 M0 (n = 118) 
T3 N2 M0 (n = 53) 
Stage IIlb (n = 100) 
T4 N0-1 M0 (n = 37) 
T4 N2 M0 (n = 43) 
Any T N3 M0 (n = 20) 
Stage IV (n = 97) 
43 20.7 93 32.0* 153 44.2t$ <0.01 
18 8.7 52 17.9" 88 25.4? <0.01 
25 12.0 41 14.1 65 18.8 0.03 
22 10.6 24 8.2 26 7.5 0.23 
8 3.8 7 2.4 10 2.9 0.59 
14 6.7 17 5.8 16 4.6 0.28 
90 43.3 110 37.8 87 25.1t§ <0.01 
39 18.8 46 15.811 31 9.0t <0.01 
24 11.5 46 15.8 48 13.9 0.59 
27 13.0 18 6.211 8 2.3t§ <0.01 
27 13.0 33 11.3 40 11.6 0.65 
10 4.8 11 3.8 16 4.6 0.99 
15 7.2 15 5.2 13 3.8 0.08 
2 1.0 7 2.4 11 3.2 0.10 
26 12.5 31 10.7 40 11.6 0.80 
Time trend analysis by )(2 test.6 
*p < 0.01, 1976 to 1980 vs 1981 to 1985. 
?p < 0.01, 1976 to 1980 vs 1986 to 1990. 
:I:p < 0.05, 1981 to 1985 vs 1986 to 1990. 
§p < 0.01, 1981 to 1985 vs 1986 to 1990. 
liP < 0.05, 1976 to 1980 vs 1981 to 1985. 
Table I I I .  Rates of exploratory thoracotomy, complete resection with lymph node dissection, and 
operation-related death 
Year of operation 
1976 to 1980 1981 to 1985 1986 to 1990 
(n = 208) (n = 291) (n = 346) 
% No. % No. % No. Time trend P 
Exploratory thoracotomy 9.1 
Complete tumor resec- 57.7 
tion with ]ymph node 
dissection 
Operation-related eath 3.8 
19/208 4.8 14/291 2.9 10/346" <0.01 
120/208 68.0 198/2917 74.6 258/346* <0.01 
8/208 3.4 10/291 0.9 3/3465§ 0.02 
Time trend analysis by X z test. 6
*p < 0.01, 1976 to 1980 vs 1986 to 1990. 
tp < 0.05, 1976 to 1980 vs 1981 to 1985. 
~+p < 0.05, 1976 to 1980 vs 1986 to 1990. 
§p < 0.05, 1981 to 1985 vs 1986 to 1990. 
period, with prominent improvement at the late 
period (p < 0.01 for the early or middle period 
versus the late period; Fig. 1, Table IV). The 5-year 
survivals of patients with p-stage I at all the study 
periods were around 70%, showing no significant 
difference. The 5-year survival rate of patients with 
p-stage II disease at the late period was 74.8%, 
showing significant improvement of prognoses com- 
pared with those at the early and middle periods 
(p < 0.05 and p < 0.01, respectively). The 5-year 
survival of patients with p-stage IIIa disease at the 
late period was 49.5%, showing significant improve- 
ment compared with those at the early and middle 
periods (7) < 0.01 for both); the 5-year survivals of 
patients with p-stage IIIa pN2 disease showed 
marked improvement at the late period, whereas 
those of patients with p-stage IIIa pT3 (NO or 1) 
disease showed no significant improvement. Among 
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1986-90(n=346) : 54.0% 
............... 1981-85(n=291) : 39.0% 
: , ~ ~ = 2 0 8 )  : 31.5% 
1986-90 vs 1981-85 :p <0.001 i 
vs 1976-80:p <0.001 ! 
1981-85 vs 1976-80 :p = 0.030 I 
0 1 2 3 4 
Years after Operation 
Fig. 1. Survival curves of all patients for the three study 
periods, 1986 through 1990, 1981 through 1985, and 1976 
through 1990. 
Survival 1.0 ~ , ~  pYl (n=31): 1 47.8% 
............ pT2 (n=87): I 28.9% 
06 i  ,, 
4 ~,,,,\ L__  
0.4 • '~ 'q ,  
! " ;~  ................. ;,,,,.,. ................... 
4 0.2 pT1 vs pT2:p<0.05 vs pT3: p< 0.01 
i pT2vs pT3: p< 0.05 
0.0 
0 1 2 3 4 5 
Years after Operation 
Fig. 2. Survival curves of pN2 patients for the three 
disease states, pT1, pT2, and pT3. 
patients with p-stage IIIa pN2 disease, there were no 
significant differences among the three study groups 
with respect o patients, histologic characteristics, 
preoperative mediastinal lymph node evaluation, 
and distribution of involved mediastinal ymph 
nodes, except for significant decrease in the number 
of patients with pT3 N2 M0 disease with poor 
prognosis (Fig. 2). The 5-year survivals of patients 
with p-stage IIIb pT4 (NO or 1) disease at the middle 
and late periods showed significant improvement 
compared with those at the early period, whereas 
those of patients with p-stage IIIb, pN3 or p-stage 
IV disease were 0% at all the study periods. 
Results of the analysis of the cases of 576 patients 
who underwent complete tumor resection with 
lymph node dissection were almost the same as 
those for all 845 patients. There was no significant 
improvement in the postoperative prognosis of 
p-stage I and p-stage IIIb diseases, whereas sig- 
nificant improvement in prognosis was observed 
for p-stage II disease and p-stage IIIa pN2 disease 
(Table V). 
Multivariate analysis of the prognostic factors. 
Results of the multivariative analysis of the prognos- 
tic factors with Cox's regression mode are shown in 
Table VI. Factors with strong influence on the 
postoperative survival were mode of operation 
(whether complete tumor resection with lymph 
node dissection was achieved, p < 0.001) and 
status of pathologic lymph node involvement (p < 
0.001). Older age proved to be another strong 
factor in poor prognosis (p < 0.001), as did male 
sex (p = 0.011). 
Discussion 
There have been many reports dealing with sur- 
vival after operation for PLC defined according to 
the current TNM classification. In two reports that 
were based on more than 1000 cases, 3'1° 5-year 
survivals were 57.0% to 75.5% among patients with 
p-stage I (pT1 or pT2 N0 M0) disease, 38.4% to 
54.1% among patients with p-stage II (pT1 or pT2 
N1 M0) disease, 15.1% to 44.2% in patients with 
p-stage Ilia (pT3 or pN2 M0), and 0.0% to 8.2% 
among patients with p-stage IIIb (pT4 or pN3 M0) 
disease. There have been only a few reports, how- 
ever, stratifying survival after operation by year of 
operation. Jie and coworkers 2 reported that there 
was no improvement in survival after operation for 
920 patients with non-small-cell lung cancer during 
the period from 1969 to 1985. In their report, 
however, patients with squamous cell carcinoma 
comprised 67.7% of the sample (623 patients), 
which seemed to be a greater ate than in other 
reports. 9 Moreover, the 5-year survival of patients 
with p-stage I disease was only 47.0%, which seems 
low compared with those in other reports)' 10 Data 
reported by Jie and coworkers 2 are not considered 
to represent exactly the present status of surgery for 
PLC. In our time trend analysis regarding survival 
after operation during the past 15 years (from 1976 
to 1990) according to the current TNM classifica- 
tion, 3 we found significant improvement from the 
early period (1976 to 1980) to the middle (1981 to 
1985) and the later (1986 to 1990) periods. 
We analyzed factors contributing to improvement 
of postoperative survival, one of which may be 
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Table IV. Five-year survivals of patients who underwent thoracotomy for PLC cancer during 1976 to 1980, 
1981 to 1985, and 1986 to 1990 
Year of  operation 
1976 to 1980 1981 to 1985 1986 to 1990 
(n = 208) (n = 291) (n = 346) 
% No. % No. % No. 
Stage I (n = 289) 68.2 43 72.6 93 75.1 !53 
Stage II (n = 72) 45.5 22 38.6 24 74.8 26*? 
Stage IIIa (n = 287) 21.7 90 29.6 110 49.5 877:~ 
T3 N0-1 M0 (n = 116) 33.5 39 42.7 46 62.5 31 
Any T N2 M0 (n = 171) 11.8 51 19,4 64 41.4 56?:) 
Stage IIIb (n = 100) 11.7 27 15,2 33 23.1 40* 
T4 N0-1 M0 (n = 37) 10.0 10 36.4 11§ 43.3 16" 
Any T N3 M0 (n = 20) 0.0 2 0.0 7 0.0 11 
Stage IV (n = 97) 6.2 26 0.0 31 0.0 40 
*p< 0.05, 1976 to 1980 vs 1986 to 1990. 
tp <0.01, 1981 to 1985 vs 1986 to 1990. 
~p < 0.01, 1976 to 1980 vs 1986 to 1990. 
§p<0.05, 1976 to 1980 vs 1981 to 1985. 
improvement of surgical technique. There were no 
differences in sex distribution among the study pe- 
riods. Older age observed at the later periods was a 
prognostic factor for a poor prognosis rather than a 
good one, as shown by the multivariate analysis (p < 
0.01). The ratio of patients with adenocarcinoma 
increased at the middle and the late periods; the 
histologic type (whether adenocarcinoma or another 
type), however, did not prove to be a dependent 
prognostic factor, as shown by the multivariate 
analysis. 
Analysis of the stage stratified by year of opera- 
tion showed an increase in the ratio of patients with 
stage I disease, which was a factor in improvement 
in the prognosis of all candidates for operation. 
Increase in the number of patients with pT1 NO M0 
disease was particularly marked, which suggests 
increase in the early detection of a lung tumor as a 
result of improvement of the diagnostic technique 
(thoracic imaging and fiberoptic bronchoscopy) and 
increase in mass examination. Decrease in the num- 
ber of patients with p-stage IIIa disease, which was 
mainly a result of the decrease in the number of 
patients with pT3 N2 M0 disease and poor progno- 
sis, also contributed to overall improvement in 
prognosis. The decrease in patients with pT3 N2 M0 
disease suggests that preoperative evaluations of the 
local tumor extension and of the status of mediasti- 
nal nodes involvement have become more accurate 
with introduction of chest CT in 1981, progress in 
speed and resolution of CT, and increased iagnos- 
tic ability of the radiologists, which has allowed the 
exact diagnosis of inoperable disease. This surmise 
is supported by the significant decrease in patients 
who underwent exploratory thoracotomy and by the 
significant increase in patients who underwent com- 
plete tumor resection. As shown by the multivariate 
analysis, whether complete tumor resection could be 
achieved is an extremely strong prognostic factor 
(p < 0.001), and exact preoperative diagnosis of 
inoperable cases is therefore considered an impor- 
tant factor in better prognosis. 
The prognoses of patients with the same stage 
disease among the study periods were compared. 
The 5-year survivals of patients with p-stage I dis- 
ease were about 70% in all study periods, which 
agreed with survivals reported by other investiga- 
tors.3, 13 The 5-year survivals of patients with p-stage 
II at the early and middle periods were 45.5% and 
38.6%, respectively, which were almost he same as 
those reported by other investigators (about 35% to 
50%).3, 10, 14, 15 On the other hand, the survival at 
the late period was extremely high (74.8%); the 
reason for this could not be clarified because of the 
small number of cases. Because the number of 
patients with p-stage II disease in a single medical 
institution is quite limited, it is necessary to conduct 
a large-scale multiinstitutional study for the exact 
evaluation of the survival after operation and adju- 
vant therapy for p-stage II disease. 14 With respect to 
p-stage Ilia disease, pT3 (N0-1) disease and pN2 
disease should be analyzed separately. The 5-year 
survivals of patients with pT3 disease without medi- 
astinal lymph node metastasis showed a tendency 
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Table V, Five-yea r survivals of patients who underwent complete tumor resection with lymph node dissection 
Year of operation 
!976 to1980 1981 to 1985 1986 to 1990 
(n = 120) (n = 198) (n = 258) 
% No. % No. % No. 
Stage I (n = 276) 73.1 43 73.7 90 72.2 145 
Stage II (n = 68) 52.6 20 40.6 22 84.9 26*? 
Stage I!Ia (n = 206) 34,3 53 36.4 82 54.5 71"~ 
T3 N0-1 M0 (n = 87) 48.0 26 49.5 36 70.9 25 
Any T N2 M0 (n = 119) 20.4 27 27.2 46 44.9 465§ 
Stage IiIb (n = 17) 0.0 4 0.0 4 11.2 16 
*p < 9.05, 1976 to 1980 vs 1986 to 1990. 
tp < 0.01, 1981 to 1985 vs 1986 to 1990. 
:~p < 0.05, 1981 to i985 vs 1986 to 1990. 
§p < 0.01, 1976 t0 1980 vs 1986 to 1990. 
Table VI. Multivariate analysis of prognostic factors 







Year of operation 
Male/female 
10 yr interval 
Nonadenocarcinoma, adenocarcinoma 
Complete tumor resection and lymph 
node dissection (not done, done) 
1 ,2 ,3 ,4  
0 ,1 ,2 ,3  
1976-1980, 1981-1985, 1986-1990 
0.01 0.67 0.5!-0.87 
<0.01 1.28 1.13-1.43 
0.72 0.98 0.78-1.23 
<0.01 0.43 0.33-0.57 
0.01 1.24 1.09-1.41 
<0.01 1.71 1.53-1.92 
<0.01 0.78 0.68-0.89 
RR, Relative risk; C/, confidence interval. 
toward improvement at the late period, although 
this was not statistically significant. The values were 
consistent with those reported by other investigators 
(33.3% to 53.7% for patients with pT3 NO M0 
disease, 17.6% to 39.0% for patients with pT3 N1 
M0 disease. 3' 10~ 16 The 5-year survival rates of pa- 
tients with pN2 disease at the early and middle 
periods were 11.8% and 19.4%, respectively, which 
were almost the same as those reported by other 
investigators (28,8%, 3 15.1%, 1° and 20.1%17), 
whereas that at the late period was extremely high 
(43.3%). The improvement in the prognosis of 
patients with pN2 disease at the later periods was 
caused by the decrease in the patients with pT3 N2 
M0 disease, which suggests that operation without 
effective induction therapy is not justified in patients 
with T3 N2 M0 disease. The 5-year survivals of 
patients with p-stage IIIb and IV disease were 
almost 0%, except for patients with p-stage IIIb pT4 
N0-1 disease during the entire study periods. Oper- 
ation should therefore be considered only when 
preoperative evaluations indicate that complete re- 
section can be achieved for T4 disease without 
mediastinal involvement. 
As clearly demonstrated by the multivariate anal- 
ysis of the prognostic factors, control of lymph node 
metastasis a key to improvement in prognosis. 
Analysis of the postoperative survivals stratified by 
stage showed significant improvement at the late 
period among patients with lymph node metastasis; 
that is, p-stage II pN1 disease or p-stage IIIa pN2 
disease. What are the main factors of improvement 
in prognosis? Operation alone evidently cannot 
achieve agood prognosis in pN2 disease; Rosell and 
coworkers!  reporte d that the 5-year survival of 
patients who underwent operation for p-stage IIIa 
non-small-Cell ung cancer, most with pN2 disease, 
was 0%. We could not determine a definite reason 
for our results being better except for the decrease 
in patient s with pT3 N2 M0 disease, which contrib- 
uted to the improvement of overall postoperative 
prognosis in patients with pN2 disease. Because 
various postoperative adjuvant chemotherapy and 
radiotherapy were employed for patients with pN1 
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and N2 disease, the efficacy of  the postoperat ive  
ad juvant  therapy should be analyzed in fur ther  
study. 
We thank Nobuyuki Hamajima, MD, MPH, Division of 
Epidemiology, Aichi Cancer Research Institute, Aichi, 
Japan, for helpful comment and critical reading of the 
statistical section of the manuscript. 
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